#Germany #Frankfurt #gene therapy #Cell Therapy #Cellex Professionals

Cellex Symposium 2025: A Global Dialogue on the Future of Cell and Gene Therapy

On November 6, 2025, Frankfurt/Main witnessed an international gathering of over 100 experts convened by Cellex Cell Professionals GmbH under the theme "The Evolving Field of Cell and Gene Therapy." Attendees included thought leaders from science, industry, clinical practice, investors, and regulatory bodies, unified by a common goal: navigating the complexities and innovations of the rapidly advancing cell and gene therapy (CGT) landscape.

Dr. Armin Ehninger, Chief Scientific Strategic Officer of Cellex, emphasized the company's commitment to pioneering advancements within CGT, stating, "Scientific excellence, collaborative exchange, reliable manufacturing, and the highest quality standards are pivotal for driving innovation in advanced therapies."

Driving Innovation in Immune Cell Therapies

The symposium commenced with a session focused on the cutting-edge developments in immune cell therapy. Keynote speaker Dr. Karl Nägler from Sofinnova Partners highlighted the intricate landscape of venture capital opportunities and the challenges that come with investing in CGT. Kenneth Locke elaborated on revolutionary methods utilizing cell-derived nanoparticles to address fundamental barriers in the activation and proliferation of T cells. Additionally, Dr. Jiri Eitler from Dresden University of Technology shared insights regarding accessibility strategies for CAR-NK therapies, paving the way for broader use across various cancer types.

Dr. Jessica Hartmann from the Paul-Ehrlich-Institute then addressed the delicate balance between innovation and the necessary frameworks for consolidating scientific breakthroughs into effective and scalable manufacturing processes. She underscored Cellex's role in establishing new benchmarks for quality in the CGT manufacturing space.

Clinical Navigation: Bridging Theory to Practice

The next segment brought to light the pivotal intersection of clinical navigation and digital innovation in therapeutic implementation. Renowned experts including Prof. Dimitrios Mougiakakos from University Hospital Magdeburg and Prof. Ralf Gold of Ruhr University Bochum showcased their groundbreaking research on CAR-T therapies aimed at treating autoimmune and neuromuscular conditions.

The emergence of outpatient CAR-T therapy models symbolized a shift in clinical practice, as presented by Prof. Christof Scheid from University Hospital Cologne. Additionally, Dr. Moritz Middeke from Cancilico demonstrated how integrating artificial intelligence into cancer diagnostics and treatment protocols can accelerate the advent of precision medicine, offering new hope for patients.

A panel discussion titled “Cell and Gene Therapy 2035: Transformative Shifts in Science, Systems, and Scale” invited diverse perspectives from stakeholders on enhancing access to CGT therapies and anticipating future innovations driven by artificial intelligence and process improvements.

Manufacturing and Quality as Enablers

The final session underscored the significance of manufacturing practices in advancing CGT. With insights from Gabriela Valentová from Johnson & Johnson on optimizing manufacturing through early data collection, the session delved into essential discussions around donor material sourcing and potential hurdles in registry integration, led by Tom Brenner from Stefan-Morsch-Stiftung.

Experts like Dr. Gunther Busam from Orchard Therapeutics detailed innovations in CAR-T manufacturing processes, emphasizing the necessity of strategic enablers such as process design and quality management to elevate scientific advancements into clinical applicability.

Networking and Collaboration: A Foundation for Growth

Beyond the scientific discourse, the Cellex Symposium 2025 fostered an atmosphere of collaboration among various professionals from multiple disciplines. Researchers, clinicians, and industry leaders engaged in dialogue aimed at enhancing therapy accessibility, harmonizing operational standards, and promoting data-driven quality control implementations within CGT manufacturing.

Prof. Gerhard Ehninger, the founder and CEO of Cellex, concluded the symposium with a statement reaffirming the importance of collective effort, asserting, "The success of the Cellex Symposium 2025 emphasizes our belief that progress in CGT hinges on scientific excellence and collaboration among many brilliant minds."

About Cellex Cell Professionals GmbH

Cellex Cell Professionals has established itself as a premier contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. Based in Cologne, Germany, Cellex boasts over a decade of experience in GMP-compliant manufacturing of autologous and allogeneic cell therapies, partnering with leading pharmaceutical and biotech companies to support their clinical development and commercial production.

To learn more about Cellex, visit www.cellex.me/en.